Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine for Oxidative Stress in COPD
NCT03956888Phase 3Completed
- Sponsor
- Siriraj Hospital
- Start
- May 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acetylcysteine in chronic obstructive pulmonary disease (COPD), sponsored by Siriraj Hospital. Primary endpoints: Level of 8-isoprostane in sputum at 4 weeks, Level of Malondialdehyde in sputum at 4 weeks and 1 more. Started May 2019; status: completed.
02
Drugs
acetylcysteine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03956888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956888.